Company profilePharmaceutical#461 of 1,318 in Pakistan✓ No DRAP alerts

WELLBORNE PHARMACHEM AND BIOLOGICALS

Pharmaceutical company · 32 brands · 29 molecules

Ranked #116 of 137 companies in Anti-Infectives

32 registered products 17 pharmaceutical brands 29 distinct molecules 0 DRAP alerts

Company overview

32
registered products
17
pharmaceutical brands
29
distinct molecules
2
therapeutic classes
0
DRAP alerts

WELLBORNE PHARMACHEM AND BIOLOGICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 32 product registrations across 29 distinct molecules. Its portfolio is concentrated in Anti-Infectives and Aminoglycoside Antibacterials. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by WELLBORNE

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infectives 1

Top molecules by brand count

Diclofenac3 brands
Artemether2 brands
Mecobalamin2 brands
Piroxicam2 brands
Cefotaxime1 brand
Cefepime1 brand
Sulbactam1 brand

Therapeutic classes

Anti-Infectives · 1Aminoglycoside Antibacterials · 1

Conditions treated

General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid1 products · Rs 325 – Rs 325
Median across source: Rs 325

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

SHROOQ PHARMACEUTICALS14 shared molecules
NEUTRO PHARMA (PVT) LTD.14 shared molecules
GLOBAL BRANDS DISTRIBUTORS13 shared molecules
BIO LABS (PVT) LTD.12 shared molecules
Albro Pharmaceuticals12 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHROOQ PHARMACEUTICALS holds 21 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCiprofloxacinDiclofenacDiclofenac Potassium
NEUTRO PHARMA (PVT) LTD. holds 126 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin

Get the full profile for WELLBORNE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.